Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3039663 | 0.99 | OPRM1 (0.32) | OPRM1OPRL1S1PR1PDCD1CD274 | |
| SCHEMBL13137169 | 0.89 | GRIN2B (0.34) | S1PR1BRD4CREBBPGRIN2B | |
| SCHEMBL13137246 | 0.89 | MAP4K1 (0.35) | OPRM1OPRL1S1PR1PDCD1CD274 | |
| SCHEMBL3043972 | 0.88 | BACE1 (0.37) | OPRM1OPRL1MAPT | |
| SCHEMBL13137140 | 0.88 | BMPR1B (0.37) | OPRM1OPRL1MAPT | |
| Hydrochloric Acid SCHEMBL3939331 | 0.88 | MAP4K1 (0.35) | OPRM1OPRL1S1PR1PDCD1CD274 | |
| Hydrochloric Acid SCHEMBL3044368 | 0.88 | PDCD1 (0.32) | OPRM1OPRL1S1PR1PDCD1CD274 | |
| SCHEMBL13137179 | 0.88 | OPRL1 (0.33) | OPRL1S1PR1 | |
| Hydrochloric Acid SCHEMBL3034125 | 0.88 | BACE1 (0.36) | OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL3044290 | 0.88 | BMPR1B (0.36) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRL1 1/4885S1PR1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.